patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_866372 | REC_0002501 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 15 | 10.2 | 71 | female | 1 | 26 | 8 | 1 | osimertinib 80 mg daily | 12.8 | true | MSS | 2026-03-15T05:35:57.461669+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_851305 | REC_0002502 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 15.7 | 76 | female | 1 | 24 | 4.1 | 2 | pembrolizumab 200 mg q3w | 15.7 | true | MSI-H | 2026-03-15T05:35:57.461901+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_279713 | REC_0002503 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 33 | 6.1 | 56 | male | 0 | 23 | 6.4 | 5 | pembrolizumab 200 mg q3w | 14.8 | true | MSS | 2026-03-15T05:35:57.462134+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_133534 | REC_0002504 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 14.4 | 67 | female | 0 | 18 | 3.5 | 2 | sotorasib 960 mg daily | 18.1 | false | MSI-H | 2026-03-15T05:35:57.462368+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_374612 | REC_0002505 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 14.2 | 59 | female | 0 | 10 | 6.6 | 10 | sotorasib 960 mg daily | 10.2 | false | MSS | 2026-03-15T05:35:57.462605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_175475 | REC_0002506 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 4.2 | 59 | male | 0 | 2 | 4.3 | 6 | sotorasib 960 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:57.462837+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_776042 | REC_0002507 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 1.5 | 66 | male | 0 | 48 | 5.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 18.9 | true | MSS | 2026-03-15T05:35:57.463069+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_181178 | REC_0002508 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 17.2 | 79 | male | 1 | 10 | 5.9 | 7 | alectinib 600 mg BID | 14.6 | false | MSI-H | 2026-03-15T05:35:57.463307+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_704819 | REC_0002509 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 14 | 62 | male | 1 | 8 | 6.5 | 5 | alectinib 600 mg BID | 13.8 | false | MSI-H | 2026-03-15T05:35:57.463543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_867716 | REC_0002510 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 1.5 | 61 | female | 1 | 4 | 5.7 | 5 | osimertinib 80 mg daily | 12 | true | MSS | 2026-03-15T05:35:57.463824+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_559006 | REC_0002511 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 10.4 | 60 | female | 0 | 13 | 6.3 | 5 | alectinib 600 mg BID | 10.1 | false | MSS | 2026-03-15T05:35:57.464063+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_229624 | REC_0002512 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 4.8 | 90 | female | 1 | 31 | 5 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.1 | true | MSS | 2026-03-15T05:35:57.464415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_181568 | REC_0002513 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 19.7 | 68 | female | 0 | 17 | 5.3 | 5 | entrectinib 600 mg daily | 9.2 | false | MSI-H | 2026-03-15T05:35:57.464653+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664107 | REC_0002514 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 22 | 11.3 | 71 | female | 0 | 4 | 6.4 | 0 | osimertinib 80 mg daily | 56.8 | true | MSS | 2026-03-15T05:35:57.464887+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295188 | REC_0002515 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 14.6 | 73 | male | 2 | 13 | 5.9 | 7 | osimertinib 80 mg daily | 10.1 | true | MSI-H | 2026-03-15T05:35:57.465125+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_524333 | REC_0002516 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 6.5 | 73 | female | 1 | 17 | 7.1 | 5 | osimertinib 80 mg daily | 9.3 | true | MSS | 2026-03-15T05:35:57.465352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940870 | REC_0002517 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 6 | 68 | male | 0 | 12 | 6.7 | 7 | pembrolizumab 200 mg q3w | 11.5 | false | MSS | 2026-03-15T05:35:57.465584+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996170 | REC_0002518 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 5.2 | 67 | female | 0 | 11 | 6.7 | 7 | entrectinib 600 mg daily | 7.3 | true | MSS | 2026-03-15T05:35:57.465816+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_917822 | REC_0002519 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 9.6 | 77 | female | 2 | 16 | 5.2 | 8 | pembrolizumab 200 mg q3w | 11.9 | false | MSS | 2026-03-15T05:35:57.466045+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_194925 | REC_0002520 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 12.4 | 61 | female | 1 | 10 | 9.3 | 6 | osimertinib 80 mg daily | 12.2 | false | MSS | 2026-03-15T05:35:57.466280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721381 | REC_0002521 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 12.3 | 71 | female | 2 | 12 | 4.6 | 1 | alectinib 600 mg BID | 17.5 | false | MSS | 2026-03-15T05:35:57.466515+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_575244 | REC_0002522 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 5.2 | 70 | male | 2 | 13 | 4.5 | 5 | pembrolizumab 200 mg q3w | 16.5 | true | MSS | 2026-03-15T05:35:57.466746+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778204 | REC_0002523 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 31 | 13.2 | 60 | female | 1 | 10 | 6.3 | 0 | osimertinib 80 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:57.467035+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602647 | REC_0002524 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 19 | 73 | female | 1 | 8 | 6.3 | 5 | entrectinib 600 mg daily | 9.3 | true | MSS | 2026-03-15T05:35:57.467274+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_357548 | REC_0002525 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 11.4 | 66 | female | 0 | 3 | 5.5 | 1 | osimertinib 80 mg daily | 23.6 | false | MSI-H | 2026-03-15T05:35:57.467505+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324481 | REC_0002526 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 15.5 | 73 | female | 1 | 10 | 6.5 | 1 | entrectinib 600 mg daily | 16.9 | false | MSS | 2026-03-15T05:35:57.467738+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140863 | REC_0002527 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 5.2 | 78 | male | 1 | 46 | 6.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.4 | false | MSS | 2026-03-15T05:35:57.467970+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_298796 | REC_0002528 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 21 | 77 | male | 2 | 15 | 7.3 | 5 | sotorasib 960 mg daily | 5.8 | false | MSI-H | 2026-03-15T05:35:57.468234+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_427407 | REC_0002529 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 6.9 | 86 | female | 1 | 15 | 7.3 | 4 | osimertinib 80 mg daily | 12.4 | false | MSS | 2026-03-15T05:35:57.468466+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757614 | REC_0002530 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 10.9 | 65 | female | 1 | 15 | 4.9 | 5 | osimertinib 80 mg daily | 7.5 | false | MSI-H | 2026-03-15T05:35:57.468703+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707944 | REC_0002531 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 17 | 69 | female | 1 | 16 | 4.7 | 4 | osimertinib 80 mg daily | 17.9 | true | MSI-H | 2026-03-15T05:35:57.468935+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_524297 | REC_0002532 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 12.5 | 70 | female | 2 | 7 | 5.3 | 2 | osimertinib 80 mg daily | 9.6 | true | MSS | 2026-03-15T05:35:57.469167+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450188 | REC_0002533 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 12.7 | 64 | male | 1 | 19 | 4.9 | 1 | osimertinib 80 mg daily | 15.3 | false | MSS | 2026-03-15T05:35:57.469402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_767956 | REC_0002534 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 9.7 | 75 | male | 1 | 10 | 4.2 | 7 | osimertinib 80 mg daily | 15.1 | false | MSS | 2026-03-15T05:35:57.469633+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482198 | REC_0002535 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 14.2 | 70 | male | 1 | 16 | 6.1 | 7 | entrectinib 600 mg daily | 9.5 | true | MSS | 2026-03-15T05:35:57.469870+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_983028 | REC_0002536 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 15.7 | 57 | female | 1 | 18 | 7.9 | 1 | osimertinib 80 mg daily | 25 | false | MSS | 2026-03-15T05:35:57.470145+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826549 | REC_0002537 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 14.8 | 61 | male | 1 | 17 | 4.3 | 1 | osimertinib 80 mg daily | 24.8 | true | MSS | 2026-03-15T05:35:57.470384+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_419746 | REC_0002538 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 12.1 | 61 | male | 0 | 13 | 4 | 4 | sotorasib 960 mg daily | 12.8 | false | MSI-H | 2026-03-15T05:35:57.470619+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_982639 | REC_0002539 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 12.8 | 78 | female | 2 | 14 | 4.7 | 4 | osimertinib 80 mg daily | 9.4 | false | MSI-H | 2026-03-15T05:35:57.470855+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748096 | REC_0002540 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.1 | 72 | female | 3 | 21 | 3.8 | 6 | osimertinib 80 mg daily | 11.1 | true | MSI-H | 2026-03-15T05:35:57.471088+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_671738 | REC_0002541 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 13.9 | 68 | female | 1 | 16 | 5.5 | 5 | osimertinib 80 mg daily | 9.7 | false | MSI-H | 2026-03-15T05:35:57.471319+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_883005 | REC_0002542 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 9.6 | 56 | female | 0 | 26 | 6.3 | 6 | entrectinib 600 mg daily | 12.4 | true | MSS | 2026-03-15T05:35:57.471548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393901 | REC_0002543 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 17 | 6.1 | 68 | female | 1 | 43 | 6 | 1 | carboplatin + paclitaxel + pembrolizumab | 23.5 | false | MSS | 2026-03-15T05:35:57.471775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_704660 | REC_0002544 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 3.6 | 67 | female | 0 | 36 | 3.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.6 | false | MSS | 2026-03-15T05:35:57.472005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664256 | REC_0002545 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 8.1 | 63 | male | 1 | 11 | 5.3 | 5 | osimertinib 80 mg daily | 11.6 | true | MSS | 2026-03-15T05:35:57.472287+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_236209 | REC_0002546 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 33 | 4.5 | 61 | male | 0 | 15 | 3.3 | 6 | pembrolizumab 200 mg q3w | 10.6 | false | MSS | 2026-03-15T05:35:57.472522+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_508868 | REC_0002547 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 10.4 | 80 | male | 2 | 17 | 7 | 6 | alectinib 600 mg BID | 11.9 | true | MSS | 2026-03-15T05:35:57.472760+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976358 | REC_0002548 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 7.5 | 65 | male | 0 | 12 | 6.5 | 2 | osimertinib 80 mg daily | 19.5 | true | MSS | 2026-03-15T05:35:57.472991+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344817 | REC_0002549 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.5 | 72 | female | 1 | 24 | 4.5 | 8 | carboplatin + paclitaxel + pembrolizumab | 5.7 | true | MSS | 2026-03-15T05:35:57.473269+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811893 | REC_0002550 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 14.2 | 58 | female | 1 | 14 | 5.4 | 4 | sotorasib 960 mg daily | 10.4 | true | MSI-H | 2026-03-15T05:35:57.473511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_146904 | REC_0002551 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 14.4 | 75 | female | 2 | 10 | 7.9 | 6 | osimertinib 80 mg daily | 4.4 | false | MSI-H | 2026-03-15T05:35:57.473748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149535 | REC_0002552 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 14.8 | 71 | male | 3 | 11 | 3.4 | 5 | osimertinib 80 mg daily | 12.9 | true | MSS | 2026-03-15T05:35:57.473983+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_935732 | REC_0002553 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 17 | 11.5 | 69 | female | 0 | 19 | 4.6 | 1 | osimertinib 80 mg daily | 10.9 | true | MSS | 2026-03-15T05:35:57.474215+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_629300 | REC_0002554 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 7 | 64 | female | 0 | 7 | 7.7 | 6 | sotorasib 960 mg daily | 12.2 | true | MSS | 2026-03-15T05:35:57.474448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_540145 | REC_0002555 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 3.8 | 60 | male | 0 | 41 | 7.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 11.1 | false | MSS | 2026-03-15T05:35:57.474680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_581298 | REC_0002556 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 15 | 70 | male | 2 | 7 | 3.4 | 5 | pembrolizumab 200 mg q3w | 12.6 | false | MSS | 2026-03-15T05:35:57.474916+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843720 | REC_0002557 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 33 | 16 | 71 | female | 1 | 19 | 5.8 | 2 | osimertinib 80 mg daily | 27.9 | true | MSI-H | 2026-03-15T05:35:57.475144+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_574248 | REC_0002558 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 13.9 | 71 | female | 1 | 7 | 3.4 | 5 | entrectinib 600 mg daily | 7.5 | false | MSS | 2026-03-15T05:35:57.475381+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_927109 | REC_0002559 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 28 | 5.9 | 77 | female | 2 | 70 | 6.9 | 0 | carboplatin + paclitaxel + pembrolizumab | 40.1 | false | MSS | 2026-03-15T05:35:57.475609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_302463 | REC_0002560 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 8.5 | 62 | male | 1 | 7 | 7.2 | 6 | osimertinib 80 mg daily | 16 | true | MSS | 2026-03-15T05:35:57.475842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_934913 | REC_0002561 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 7 | 65 | male | 0 | 8 | 6.4 | 5 | sotorasib 960 mg daily | 12.2 | false | MSS | 2026-03-15T05:35:57.476153+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_444647 | REC_0002562 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 8 | 65 | male | 1 | 9 | 5.4 | 2 | osimertinib 80 mg daily | 17.3 | true | MSS | 2026-03-15T05:35:57.476454+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714909 | REC_0002563 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 24 | 13.1 | 72 | male | 2 | 18 | 5.4 | 0 | alectinib 600 mg BID | 24.6 | false | MSS | 2026-03-15T05:35:57.476697+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593403 | REC_0002564 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 14.3 | 61 | male | 0 | 10 | 7.2 | 3 | entrectinib 600 mg daily | 13.1 | false | MSI-H | 2026-03-15T05:35:57.476935+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124009 | REC_0002565 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 11.8 | 61 | male | 0 | 15 | 2 | 6 | osimertinib 80 mg daily | 7 | false | MSI-H | 2026-03-15T05:35:57.477174+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417493 | REC_0002566 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 4 | 68 | female | 0 | 32 | 6 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.2 | true | MSS | 2026-03-15T05:35:57.477403+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356450 | REC_0002567 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 5.2 | 76 | female | 3 | 10 | 5.6 | 2 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.477632+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376674 | REC_0002568 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 14 | 12.7 | 56 | male | 1 | 12 | 6.8 | 5 | osimertinib 80 mg daily | 5.2 | true | MSI-H | 2026-03-15T05:35:57.477865+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_770557 | REC_0002569 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 13.7 | 73 | female | 2 | 16 | 5 | 7 | sotorasib 960 mg daily | 13.9 | true | MSS | 2026-03-15T05:35:57.478098+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_495080 | REC_0002570 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 9.4 | 63 | male | 1 | 16 | 4.3 | 6 | osimertinib 80 mg daily | 11.9 | true | MSS | 2026-03-15T05:35:57.478330+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_620235 | REC_0002571 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 12.1 | 67 | female | 0 | 17 | 6.5 | 2 | osimertinib 80 mg daily | 15.1 | true | MSI-H | 2026-03-15T05:35:57.478566+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_651970 | REC_0002572 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 14.1 | 57 | female | 0 | 5 | 4.8 | 6 | sotorasib 960 mg daily | 11.8 | true | MSS | 2026-03-15T05:35:57.478810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_841557 | REC_0002573 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 6.5 | 70 | female | 1 | 16 | 4.9 | 6 | pembrolizumab 200 mg q3w | 22.9 | false | MSS | 2026-03-15T05:35:57.479060+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_878515 | REC_0002574 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 12.4 | 62 | female | 0 | 16 | 4.3 | 7 | alectinib 600 mg BID | 13.7 | true | MSS | 2026-03-15T05:35:57.479318+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554236 | REC_0002575 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 33 | 6.7 | 76 | female | 2 | 5 | 4.8 | 0 | carboplatin + paclitaxel + pembrolizumab | 23 | true | MSS | 2026-03-15T05:35:57.479678+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_423600 | REC_0002576 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 11.2 | 67 | female | 0 | 20 | 7 | 8 | osimertinib 80 mg daily | 9.8 | true | MSS | 2026-03-15T05:35:57.479926+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_463639 | REC_0002577 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 8.7 | 61 | male | 1 | 13 | 6 | 6 | entrectinib 600 mg daily | 12.6 | true | MSS | 2026-03-15T05:35:57.480214+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_884742 | REC_0002578 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 13.7 | 69 | female | 1 | 14 | 5.4 | 5 | sotorasib 960 mg daily | 17.4 | false | MSI-H | 2026-03-15T05:35:57.480457+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690121 | REC_0002579 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 5 | 74 | female | 1 | 33 | 6.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.5 | false | MSS | 2026-03-15T05:35:57.480688+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442844 | REC_0002580 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 7 | 62 | male | 0 | 74 | 6.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.2 | false | MSS | 2026-03-15T05:35:57.480922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_537337 | REC_0002581 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 12.8 | 70 | female | 1 | 18 | 6.4 | 6 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:57.481154+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_292075 | REC_0002582 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 13.8 | 68 | female | 1 | 9 | 6.5 | 5 | entrectinib 600 mg daily | 13.3 | true | MSI-H | 2026-03-15T05:35:57.481385+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_717491 | REC_0002583 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 13.3 | 62 | male | 0 | 28 | 3.5 | 4 | entrectinib 600 mg daily | 12.5 | true | MSI-H | 2026-03-15T05:35:57.481622+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_903686 | REC_0002584 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 11.9 | 73 | female | 3 | 14 | 6.9 | 3 | entrectinib 600 mg daily | 18.3 | true | MSS | 2026-03-15T05:35:57.481860+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_517971 | REC_0002585 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 20 | 4.7 | 64 | female | 1 | 16 | 5.2 | 2 | pembrolizumab 200 mg q3w | 20.4 | true | MSS | 2026-03-15T05:35:57.482092+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_669676 | REC_0002586 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 9.6 | 62 | male | 0 | 9 | 5.3 | 2 | pembrolizumab 200 mg q3w | 4.8 | true | MSS | 2026-03-15T05:35:57.482327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242379 | REC_0002587 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 12.5 | 82 | male | 2 | 10 | 4.1 | 2 | osimertinib 80 mg daily | 19.6 | true | MSI-H | 2026-03-15T05:35:57.482568+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136421 | REC_0002588 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 15.3 | 76 | female | 2 | 11 | 5.2 | 1 | entrectinib 600 mg daily | 21.9 | false | MSS | 2026-03-15T05:35:57.482858+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930834 | REC_0002589 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 15.2 | 75 | male | 1 | 18 | 6.4 | 7 | alectinib 600 mg BID | 12.1 | true | MSS | 2026-03-15T05:35:57.483097+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242458 | REC_0002590 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 2.8 | 70 | female | 1 | 44 | 6.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 21.6 | true | MSS | 2026-03-15T05:35:57.483329+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557397 | REC_0002591 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 6 | 74 | male | 1 | 45 | 3.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.7 | true | MSS | 2026-03-15T05:35:57.483564+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932386 | REC_0002592 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 17.7 | 78 | female | 1 | 4 | 2 | 5 | entrectinib 600 mg daily | 12.1 | false | MSS | 2026-03-15T05:35:57.483795+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378815 | REC_0002593 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 9.8 | 63 | female | 0 | 10 | 4.8 | 6 | alectinib 600 mg BID | 11.1 | true | MSS | 2026-03-15T05:35:57.484025+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_943334 | REC_0002594 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 7.9 | 71 | female | 1 | 39 | 6.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 9.4 | false | MSS | 2026-03-15T05:35:57.484316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_600500 | REC_0002595 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 9.4 | 85 | female | 1 | 10 | 6 | 6 | entrectinib 600 mg daily | 14.5 | true | MSS | 2026-03-15T05:35:57.484550+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811448 | REC_0002596 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 15.8 | 70 | female | 1 | 4 | 5.6 | 2 | osimertinib 80 mg daily | 20.7 | true | MSI-H | 2026-03-15T05:35:57.484782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239304 | REC_0002597 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 13 | 55 | female | 1 | 17 | 4.6 | 5 | entrectinib 600 mg daily | 10.5 | true | MSI-H | 2026-03-15T05:35:57.485019+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_185634 | REC_0002598 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 12.9 | 75 | female | 1 | 15 | 6.3 | 2 | osimertinib 80 mg daily | 23.1 | false | MSI-H | 2026-03-15T05:35:57.485254+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_805089 | REC_0002599 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 12.8 | 67 | female | 0 | 24 | 2.9 | 0 | sotorasib 960 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:57.485486+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322332 | REC_0002600 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 10.4 | 59 | male | 1 | 4 | 5.1 | 6 | alectinib 600 mg BID | 19.7 | false | MSI-H | 2026-03-15T05:35:57.485720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.